WEX Names New CEO and Strengthens Management Team
December 20, 2005
Vancouver, BC (December 20, 2005) - WEX Pharmaceuticals Inc. (the "Company") is pleased to announce that Dr. Edge Wang has been named President and Chief Executive Officer of the Company.
Dr. Edge Wang was elected as a member of the Board of Directors of the company in August 2005 and became the Interim CEO shortly afterwards.
"Our primary goal is to complete our clinical trials on Tectin™ and to commercialize this product in the most expeditious manner," said Dr. Edge Wang. "We will also concentrate on increasing WEX's pipeline. I am determined to build a strong team to grow WEX into a global leader in pain management."
Dr. Jean Bourgouin, Chief Medical Officer, has been appointed Executive Vice President of the Company with further responsibilities and authority. "Since joining the Company in March, Dr. Bourgouin has led the clinical team in achieving significant progress in our clinical studies." said Dr. Edge Wang.
Trevor Sinclair has been appointed as Interim Chief Financial Officer of the Company as WEX continues to search for a permanent CFO. Mr. Sinclair, a chartered accountant, has 10 years of experience in accounting and finance and has worked with both private and public companies providing professional services in financial reporting, tax consulting and corporate compliance.
Dr. Don Qiu has been appointed V.P. Operations of the Company. Dr. Qui has extensive experience within the biotechnology and venture capital industries. Dr. Qui has an MBA, PhD (Medicinal Chemistry), and a Bachelor of Science.
The members of the new management team also consist of Dr. Anh Ho Ngoc, V.P. Regulatory Affairs & Quality Assurance, Mr. Don Evans, V.P. Corporate Communication, and Dr. Euan Taylor, V.P. Intellectual Property.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.
Forward Looking Statements
This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements.
The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
For additional information on our products, visit us at www.wexpharma.com or call Don Evans, V.P. Corporate Communications at 604-683-8880 or 1-800-722-7549.
